Loading clinical trials...
Loading clinical trials...
This clinical trial studies how well FDG-PET/CT measures early response in patients with stage III-IV melanoma who are receiving chemotherapy. Positron emission tomography (PET)/computed tomography (C...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Collaborators
NCT01303341 · Advanced Malignant Solid Neoplasm, Recurrent Melanoma, and more
NCT00937937 · Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma, and more
NCT04284774 · Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, and more
NCT01708941 · Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, and more
NCT01134614 · Advanced Melanoma, Metastatic Melanoma, and more
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions